Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 5:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Newly Diagnosed Type 1 Diabetes Clear all
Completed Phase 2 Interventional Results available

Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)

NCT00529191
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Atorvastatin, Placebo
Drug · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 1, 2026, 5:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

NCT06783309
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus, Type 1 Diabetes in Adolescence, Type 1 Diabetes in Children, Type 1 Diabetes (Juvenile Onset), Type 1 Diabetes, Type 1 Diabetes Patients, Type 1 Diabetes Mellitis
Interventions
CNP-103, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
45
States / cities
Tucson, Arizona • Newport Beach, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 1, 2026, 5:39 PM EDT
Active, not recruiting Not applicable Interventional

Community Health Workers in Pediatric Patients With Newly Diagnosed Type 1 Diabetes

NCT04238949
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Psychosocial Problem, Compliance, Patient, Health Behavior
Interventions
Community Health Worker added to diabetes team
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Fast Track CSII Using a Novel Device in Young Children With Newly Diagnosed T1DM

NCT00476788
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Omnipod Insulin Management System
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year to 8 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 1, 2026, 5:39 PM EDT
Recruiting Not applicable Interventional

Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes

NCT05899166
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Ketogenic diet, food delivery and education, Standard diet, food delivery and education
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 12 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Not applicable Interventional

Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study

NCT04336969
View directory record Official record
Conditions
Type1diabetes
Interventions
4T Education and Care
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 21 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Steamboat Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 1 Interventional Results available

Effect of Prebiotics on the Gut Microbiome Profile and Beta Cell Function

NCT04114357
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Acetylated and Butyrylated High Amylose Maize Starch
Drug
Lead sponsor
Indiana University
Other
Eligibility
11 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 1, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

NCT02044848
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 35 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

NCT02443155
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
NNC0114-0006, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
La Jolla, California • Northridge, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 1, 2026, 5:39 PM EDT
Terminated Phase 3 Interventional

A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT

NCT00751842
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
rhGAD65, Placebo
Drug
Lead sponsor
Diamyd Therapeutics AB
Industry
Eligibility
10 Years to 20 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 1, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional

Probiotics in Newly Diagnosed T1D

NCT04141761
View directory record Official record
Conditions
Type 1 Diabetes, Type1diabetes, Type 1 Diabetes Mellitus
Interventions
Visbiome, Placebo
Dietary Supplement · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
5 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 1 Interventional

R-5280 in Newly Diagnosed Patients With Type 1 Diabetes

NCT06057454
View directory record Official record
Conditions
Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
Interventions
R-5280, Placebo
Drug · Other
Lead sponsor
Rise Therapeutics LLC
Industry
Eligibility
11 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Plantation, Florida • Rochester, Minnesota • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 1, 2026, 5:39 PM EDT
Not yet recruiting Not applicable Interventional

Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D

NCT07501338
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem Automated Insulin Delivery System
Device
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 26 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 1, 2026, 5:39 PM EDT
Terminated Phase 2 Interventional Results available

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

NCT00515099
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Antithymocyte globulin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
9
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

NCT00947427
View directory record Official record
Conditions
Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
Interventions
canakinumab (anti IL-1beta), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 2 Interventional Results available

Rituximab in New Onset Type 1 Diabetes

NCT00279305
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Anti-CD20 (rituximab), Placebo Comparator
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes

NCT00645840
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Anakinra
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 1, 2026, 5:39 PM EDT
Active, not recruiting Phase 2 Interventional

Reducing Innate Inflammation in New Onset Type 1 Diabetes

NCT04335656
View directory record Official record
Conditions
Type 1 Diabetes, type1diabetes, Type 1 Diabetes Mellitus
Interventions
Lactiplantibacillus plantarum, Placebo
Dietary Supplement · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1

NCT00678886
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
otelixizumab infusion plus physician determined standard of care, placebo infusion plus physician determined standard of care
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Costa Mesa, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Interferon-Alpha for Diabetes Mellitus Type 1

NCT00024518
View directory record Official record
Conditions
Insulin-Dependent Diabetes Mellitus
Interventions
30,000 units hrINF-alpha, 5,000 hrINF-alpha, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 25 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
5
States / cities
Bethesda, Maryland • Saint Paul, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 1, 2026, 5:39 PM EDT
Terminated Not applicable Interventional Results available

Effectiveness of Using Educational Modules Via Bedside Tablet in Newly Diagnosed Type 1 Diabetes

NCT03534193
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Molly Center Diabetes Care Guide (Paper-based), Tablet based interactive diabetes education modules
Other
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

NCT01103284
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
DiaPep277, Placebo
Drug
Lead sponsor
Andromeda Biotech Ltd.
Industry
Eligibility
20 Years to 45 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
26
States / cities
Los Gatos, California • Modesto, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Not applicable Interventional Results available

Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)

NCT00357890
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Insulin pump therapy, Multiple daily injections using insulin glargine + rapid acting analog
Device · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 1, 2026, 5:39 PM EDT
Completed Phase 2 Interventional

Prevention of Diabetes Progression Trial (PDPT)

NCT00198146
View directory record Official record
Conditions
Newly Diagnosed With Type 1 Diabetes
Interventions
Zenapax
Drug
Lead sponsor
Indiana University
Other
Eligibility
2 Years to 40 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 1, 2026, 5:39 PM EDT